Atomo is Leading the Future of Diagnostics
Our unique, patented proprietary technologies improve rapid diagnostics testing by elevating ease-of-use and performance.
Atomo’s innovative Rapid Diagnostic Test (RDT) platforms simplify procedures, mitigate common user errors and enhance test performance. Atomo products are currently approved for distribution in over 40 countries.
COVID-19 Test
Atomo’s platform is a natural fit for a fast, accurate point of care diagnostic for COVID-19. Atomo offers an antigen test for the qualitative detection of nucleocapsid protein antigens specific to the SARS-CoV-2 virus, as well as an antibody test to indicate if a user has protection from the virus.
HIV 1&2 Test
Atomo offers the world’s first integrated, blood-based rapid diagnostic test (RDT) for HIV screening. Recognized globally for innovative design, performance and ease-of-use. With 99.6% specificity, 99.6% sensitivity, low blood volume and a 24 month shelf life, this test could save 40,000 lives per year in Africa alone.
Develop Future Tests With Us
Atomo’s unique technology presents an opportunity to improve existing products on the market with superior usability. Our integrated platforms can help users easily perform the tests on their own and improve performance, speed and reliability in a professional clinical setting.
We welcome dialogue with forward-thinking diagnostic partners who would like to explore co-developing tests for infectious diseases, allergy sensitivities, women’s health, men’s health, sexual health, heart health and other applications.
